Sucampo Pharmaceuticals (SCMP) Rating Increased to Buy at BidaskClub

Sucampo Pharmaceuticals (NASDAQ:SCMP) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

SCMP has been the topic of a number of other research reports. B. Riley began coverage on shares of Sucampo Pharmaceuticals in a research note on Tuesday, November 14th. They set a “buy” rating and a $14.00 target price on the stock. Mizuho lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $14.00 to $12.00 in a research note on Tuesday, October 3rd. UBS cut their target price on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. Finally, ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $16.40.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $14.95 on Tuesday. The firm has a market cap of $627.25, a PE ratio of 9.21, a PEG ratio of 4.00 and a beta of 1.47. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $17.24.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. The firm had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 EPS. sell-side analysts forecast that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.

In related news, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total transaction of $12,000,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.13% of the company’s stock.

A number of large investors have recently bought and sold shares of SCMP. Louisiana State Employees Retirement System raised its holdings in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 100 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Sucampo Pharmaceuticals in the second quarter worth about $117,000. Pinnacle Associates Ltd. purchased a new position in Sucampo Pharmaceuticals in the second quarter worth about $122,000. Trexquant Investment LP purchased a new position in Sucampo Pharmaceuticals in the third quarter worth about $122,000. Finally, SG Americas Securities LLC raised its holdings in Sucampo Pharmaceuticals by 5.6% in the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 631 shares during the last quarter. 65.31% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals (SCMP) Rating Increased to Buy at BidaskClub” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/12/07/sucampo-pharmaceuticals-scmp-rating-increased-to-buy-at-bidaskclub.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply